JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2157446, encodeId=2d6d215e44647, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;综述 经验分享：2023-8-21 received 2023-8-22 first revision 2023-8-30 second revision 2023-9-1 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ae8495390, createdName=ms1000001342961891, createdTime=Wed Sep 13 00:24:55 CST 2023, time=2023-09-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161407, encodeId=9aed216140ee1, content=求endnote格式 qq873770829, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Sat Oct 07 20:38:10 CST 2023, time=2023-10-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2157417, encodeId=4ebd215e41773, content=偏重的研究方向：肿瘤;综述 经验分享：Submission received 2023-8-15 Submission is under technical check 2023-8-15 Submission passed technical check 2023-8-16 Submission under peer review 2023-8-15 1 Reviewer accepted 2023-9-1 2 Reviewer accepted 2023-9-4 1 Reviewer report received 2023-09-11 Awaiting , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue Sep 12 22:20:02 CST 2023, time=2023-09-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2157661, encodeId=e421215e66126, content=集中回答一下，此期刊24年1月1号后会变成完全OA期刊。从今年9月13号以后提交的文章如果接收发表将支付APC。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff46407323, createdName=ms5000000493892071, createdTime=Thu Sep 14 13:22:04 CST 2023, time=2023-09-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2154696, encodeId=82242154696a6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：生信+WB验证;肿瘤 经验分享：记录一下，今天距离我投稿刚满一个月，目前状态依然是正在邀请5个审稿人，求求了，审稿人们接受审稿吧~等着毕业咧，等不起哇~（接评论区大神们的accept，接心软审稿人~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884e8240952, createdName=ms7000001703629541, createdTime=Sat Aug 26 17:10:22 CST 2023, time=2023-08-26, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向：肝癌 经验分享：刚刚一个月还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160146, encodeId=dc1a2160146c3, content=请问大家track all subbmission这个选项还有吗？从昨天开始我的就不见了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c18483515, createdName=ms8000001640264275, createdTime=Thu Sep 28 08:36:28 CST 2023, time=2023-09-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2159882, encodeId=10d6215988257, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：垃圾期刊，谁投谁后悔，不复当年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Tue Sep 26 20:52:53 CST 2023, time=2023-09-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161005, encodeId=cf48216100509, content=偏重的研究方向：泌尿外科;肿瘤;影像学 经验分享：一个月了，还是没有审稿人接受审稿，会怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2586476968, createdName=ms4000001917969473, createdTime=Thu Oct 05 09:52:57 CST 2023, time=2023-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157694, encodeId=6e5c215e694ca, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：当天投，当天拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9278140959, createdName=ms3000001761424859, createdTime=Thu Sep 14 16:09:53 CST 2023, time=2023-09-14, status=1, ipAttribution=山西省)]

2023-09-13 ms1000001342961891 来自江苏省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤;综述
经验分享：2023-8-21 received
2023-8-22 first revision
2023-8-30 second revision
2023-9-1 accepted

29 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157446, encodeId=2d6d215e44647, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;综述 经验分享：2023-8-21 received 2023-8-22 first revision 2023-8-30 second revision 2023-9-1 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ae8495390, createdName=ms1000001342961891, createdTime=Wed Sep 13 00:24:55 CST 2023, time=2023-09-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161407, encodeId=9aed216140ee1, content=求endnote格式 qq873770829, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Sat Oct 07 20:38:10 CST 2023, time=2023-10-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2157417, encodeId=4ebd215e41773, content=偏重的研究方向：肿瘤;综述 经验分享：Submission received 2023-8-15 Submission is under technical check 2023-8-15 Submission passed technical check 2023-8-16 Submission under peer review 2023-8-15 1 Reviewer accepted 2023-9-1 2 Reviewer accepted 2023-9-4 1 Reviewer report received 2023-09-11 Awaiting , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue Sep 12 22:20:02 CST 2023, time=2023-09-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2157661, encodeId=e421215e66126, content=集中回答一下，此期刊24年1月1号后会变成完全OA期刊。从今年9月13号以后提交的文章如果接收发表将支付APC。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff46407323, createdName=ms5000000493892071, createdTime=Thu Sep 14 13:22:04 CST 2023, time=2023-09-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2154696, encodeId=82242154696a6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：生信+WB验证;肿瘤 经验分享：记录一下，今天距离我投稿刚满一个月，目前状态依然是正在邀请5个审稿人，求求了，审稿人们接受审稿吧~等着毕业咧，等不起哇~（接评论区大神们的accept，接心软审稿人~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884e8240952, createdName=ms7000001703629541, createdTime=Sat Aug 26 17:10:22 CST 2023, time=2023-08-26, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向：肝癌 经验分享：刚刚一个月还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160146, encodeId=dc1a2160146c3, content=请问大家track all subbmission这个选项还有吗？从昨天开始我的就不见了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c18483515, createdName=ms8000001640264275, createdTime=Thu Sep 28 08:36:28 CST 2023, time=2023-09-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2159882, encodeId=10d6215988257, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：垃圾期刊，谁投谁后悔，不复当年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Tue Sep 26 20:52:53 CST 2023, time=2023-09-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161005, encodeId=cf48216100509, content=偏重的研究方向：泌尿外科;肿瘤;影像学 经验分享：一个月了，还是没有审稿人接受审稿，会怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2586476968, createdName=ms4000001917969473, createdTime=Thu Oct 05 09:52:57 CST 2023, time=2023-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157694, encodeId=6e5c215e694ca, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：当天投，当天拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9278140959, createdName=ms3000001761424859, createdTime=Thu Sep 14 16:09:53 CST 2023, time=2023-09-14, status=1, ipAttribution=山西省)]

2023-10-07 可乐雪碧来自上海

求endnote格式 qq873770829

23 0

[GetPortalCommentsPageByObjectIdResponse(id=2157446, encodeId=2d6d215e44647, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;综述 经验分享：2023-8-21 received 2023-8-22 first revision 2023-8-30 second revision 2023-9-1 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ae8495390, createdName=ms1000001342961891, createdTime=Wed Sep 13 00:24:55 CST 2023, time=2023-09-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161407, encodeId=9aed216140ee1, content=求endnote格式 qq873770829, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Sat Oct 07 20:38:10 CST 2023, time=2023-10-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2157417, encodeId=4ebd215e41773, content=偏重的研究方向：肿瘤;综述 经验分享：Submission received 2023-8-15 Submission is under technical check 2023-8-15 Submission passed technical check 2023-8-16 Submission under peer review 2023-8-15 1 Reviewer accepted 2023-9-1 2 Reviewer accepted 2023-9-4 1 Reviewer report received 2023-09-11 Awaiting , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue Sep 12 22:20:02 CST 2023, time=2023-09-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2157661, encodeId=e421215e66126, content=集中回答一下，此期刊24年1月1号后会变成完全OA期刊。从今年9月13号以后提交的文章如果接收发表将支付APC。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff46407323, createdName=ms5000000493892071, createdTime=Thu Sep 14 13:22:04 CST 2023, time=2023-09-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2154696, encodeId=82242154696a6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：生信+WB验证;肿瘤 经验分享：记录一下，今天距离我投稿刚满一个月，目前状态依然是正在邀请5个审稿人，求求了，审稿人们接受审稿吧~等着毕业咧，等不起哇~（接评论区大神们的accept，接心软审稿人~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884e8240952, createdName=ms7000001703629541, createdTime=Sat Aug 26 17:10:22 CST 2023, time=2023-08-26, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向：肝癌 经验分享：刚刚一个月还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160146, encodeId=dc1a2160146c3, content=请问大家track all subbmission这个选项还有吗？从昨天开始我的就不见了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c18483515, createdName=ms8000001640264275, createdTime=Thu Sep 28 08:36:28 CST 2023, time=2023-09-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2159882, encodeId=10d6215988257, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：垃圾期刊，谁投谁后悔，不复当年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Tue Sep 26 20:52:53 CST 2023, time=2023-09-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161005, encodeId=cf48216100509, content=偏重的研究方向：泌尿外科;肿瘤;影像学 经验分享：一个月了，还是没有审稿人接受审稿，会怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2586476968, createdName=ms4000001917969473, createdTime=Thu Oct 05 09:52:57 CST 2023, time=2023-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157694, encodeId=6e5c215e694ca, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：当天投，当天拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9278140959, createdName=ms3000001761424859, createdTime=Thu Sep 14 16:09:53 CST 2023, time=2023-09-14, status=1, ipAttribution=山西省)]

2023-09-12 胸外科小大夫来自辽宁省

偏重的研究方向：肿瘤;综述
经验分享：Submission received 2023-8-15 Submission is under technical check 2023-8-15 Submission passed technical check 2023-8-16 Submission under peer review 2023-8-15 1 Reviewer accepted 2023-9-1 2 Reviewer accepted 2023-9-4 1 Reviewer report received 2023-09-11 Awaiting

25 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157446, encodeId=2d6d215e44647, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;综述 经验分享：2023-8-21 received 2023-8-22 first revision 2023-8-30 second revision 2023-9-1 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ae8495390, createdName=ms1000001342961891, createdTime=Wed Sep 13 00:24:55 CST 2023, time=2023-09-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161407, encodeId=9aed216140ee1, content=求endnote格式 qq873770829, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Sat Oct 07 20:38:10 CST 2023, time=2023-10-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2157417, encodeId=4ebd215e41773, content=偏重的研究方向：肿瘤;综述 经验分享：Submission received 2023-8-15 Submission is under technical check 2023-8-15 Submission passed technical check 2023-8-16 Submission under peer review 2023-8-15 1 Reviewer accepted 2023-9-1 2 Reviewer accepted 2023-9-4 1 Reviewer report received 2023-09-11 Awaiting , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue Sep 12 22:20:02 CST 2023, time=2023-09-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2157661, encodeId=e421215e66126, content=集中回答一下，此期刊24年1月1号后会变成完全OA期刊。从今年9月13号以后提交的文章如果接收发表将支付APC。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff46407323, createdName=ms5000000493892071, createdTime=Thu Sep 14 13:22:04 CST 2023, time=2023-09-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2154696, encodeId=82242154696a6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：生信+WB验证;肿瘤 经验分享：记录一下，今天距离我投稿刚满一个月，目前状态依然是正在邀请5个审稿人，求求了，审稿人们接受审稿吧~等着毕业咧，等不起哇~（接评论区大神们的accept，接心软审稿人~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884e8240952, createdName=ms7000001703629541, createdTime=Sat Aug 26 17:10:22 CST 2023, time=2023-08-26, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向：肝癌 经验分享：刚刚一个月还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160146, encodeId=dc1a2160146c3, content=请问大家track all subbmission这个选项还有吗？从昨天开始我的就不见了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c18483515, createdName=ms8000001640264275, createdTime=Thu Sep 28 08:36:28 CST 2023, time=2023-09-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2159882, encodeId=10d6215988257, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：垃圾期刊，谁投谁后悔，不复当年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Tue Sep 26 20:52:53 CST 2023, time=2023-09-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161005, encodeId=cf48216100509, content=偏重的研究方向：泌尿外科;肿瘤;影像学 经验分享：一个月了，还是没有审稿人接受审稿，会怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2586476968, createdName=ms4000001917969473, createdTime=Thu Oct 05 09:52:57 CST 2023, time=2023-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157694, encodeId=6e5c215e694ca, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：当天投，当天拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9278140959, createdName=ms3000001761424859, createdTime=Thu Sep 14 16:09:53 CST 2023, time=2023-09-14, status=1, ipAttribution=山西省)]

2023-09-14 ms5000000493892071 来自吉林省

集中回答一下，此期刊24年1月1号后会变成完全OA期刊。从今年9月13号以后提交的文章如果接收发表将支付APC。

18 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157446, encodeId=2d6d215e44647, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;综述 经验分享：2023-8-21 received 2023-8-22 first revision 2023-8-30 second revision 2023-9-1 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ae8495390, createdName=ms1000001342961891, createdTime=Wed Sep 13 00:24:55 CST 2023, time=2023-09-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161407, encodeId=9aed216140ee1, content=求endnote格式 qq873770829, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Sat Oct 07 20:38:10 CST 2023, time=2023-10-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2157417, encodeId=4ebd215e41773, content=偏重的研究方向：肿瘤;综述 经验分享：Submission received 2023-8-15 Submission is under technical check 2023-8-15 Submission passed technical check 2023-8-16 Submission under peer review 2023-8-15 1 Reviewer accepted 2023-9-1 2 Reviewer accepted 2023-9-4 1 Reviewer report received 2023-09-11 Awaiting , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue Sep 12 22:20:02 CST 2023, time=2023-09-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2157661, encodeId=e421215e66126, content=集中回答一下，此期刊24年1月1号后会变成完全OA期刊。从今年9月13号以后提交的文章如果接收发表将支付APC。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff46407323, createdName=ms5000000493892071, createdTime=Thu Sep 14 13:22:04 CST 2023, time=2023-09-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2154696, encodeId=82242154696a6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：生信+WB验证;肿瘤 经验分享：记录一下，今天距离我投稿刚满一个月，目前状态依然是正在邀请5个审稿人，求求了，审稿人们接受审稿吧~等着毕业咧，等不起哇~（接评论区大神们的accept，接心软审稿人~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884e8240952, createdName=ms7000001703629541, createdTime=Sat Aug 26 17:10:22 CST 2023, time=2023-08-26, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向：肝癌 经验分享：刚刚一个月还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160146, encodeId=dc1a2160146c3, content=请问大家track all subbmission这个选项还有吗？从昨天开始我的就不见了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c18483515, createdName=ms8000001640264275, createdTime=Thu Sep 28 08:36:28 CST 2023, time=2023-09-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2159882, encodeId=10d6215988257, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：垃圾期刊，谁投谁后悔，不复当年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Tue Sep 26 20:52:53 CST 2023, time=2023-09-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161005, encodeId=cf48216100509, content=偏重的研究方向：泌尿外科;肿瘤;影像学 经验分享：一个月了，还是没有审稿人接受审稿，会怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2586476968, createdName=ms4000001917969473, createdTime=Thu Oct 05 09:52:57 CST 2023, time=2023-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157694, encodeId=6e5c215e694ca, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：当天投，当天拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9278140959, createdName=ms3000001761424859, createdTime=Thu Sep 14 16:09:53 CST 2023, time=2023-09-14, status=1, ipAttribution=山西省)]

2023-08-26 ms7000001703629541 来自甘肃省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：生信+WB验证;肿瘤
经验分享：记录一下，今天距离我投稿刚满一个月，目前状态依然是正在邀请5个审稿人，求求了，审稿人们接受审稿吧~等着毕业咧，等不起哇~（接评论区大神们的accept，接心软审稿人~~~）

42 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157446, encodeId=2d6d215e44647, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;综述 经验分享：2023-8-21 received 2023-8-22 first revision 2023-8-30 second revision 2023-9-1 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ae8495390, createdName=ms1000001342961891, createdTime=Wed Sep 13 00:24:55 CST 2023, time=2023-09-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161407, encodeId=9aed216140ee1, content=求endnote格式 qq873770829, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Sat Oct 07 20:38:10 CST 2023, time=2023-10-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2157417, encodeId=4ebd215e41773, content=偏重的研究方向：肿瘤;综述 经验分享：Submission received 2023-8-15 Submission is under technical check 2023-8-15 Submission passed technical check 2023-8-16 Submission under peer review 2023-8-15 1 Reviewer accepted 2023-9-1 2 Reviewer accepted 2023-9-4 1 Reviewer report received 2023-09-11 Awaiting , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue Sep 12 22:20:02 CST 2023, time=2023-09-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2157661, encodeId=e421215e66126, content=集中回答一下，此期刊24年1月1号后会变成完全OA期刊。从今年9月13号以后提交的文章如果接收发表将支付APC。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff46407323, createdName=ms5000000493892071, createdTime=Thu Sep 14 13:22:04 CST 2023, time=2023-09-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2154696, encodeId=82242154696a6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：生信+WB验证;肿瘤 经验分享：记录一下，今天距离我投稿刚满一个月，目前状态依然是正在邀请5个审稿人，求求了，审稿人们接受审稿吧~等着毕业咧，等不起哇~（接评论区大神们的accept，接心软审稿人~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884e8240952, createdName=ms7000001703629541, createdTime=Sat Aug 26 17:10:22 CST 2023, time=2023-08-26, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向：肝癌 经验分享：刚刚一个月还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160146, encodeId=dc1a2160146c3, content=请问大家track all subbmission这个选项还有吗？从昨天开始我的就不见了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c18483515, createdName=ms8000001640264275, createdTime=Thu Sep 28 08:36:28 CST 2023, time=2023-09-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2159882, encodeId=10d6215988257, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：垃圾期刊，谁投谁后悔，不复当年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Tue Sep 26 20:52:53 CST 2023, time=2023-09-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161005, encodeId=cf48216100509, content=偏重的研究方向：泌尿外科;肿瘤;影像学 经验分享：一个月了，还是没有审稿人接受审稿，会怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2586476968, createdName=ms4000001917969473, createdTime=Thu Oct 05 09:52:57 CST 2023, time=2023-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157694, encodeId=6e5c215e694ca, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：当天投，当天拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9278140959, createdName=ms3000001761424859, createdTime=Thu Sep 14 16:09:53 CST 2023, time=2023-09-14, status=1, ipAttribution=山西省)]

2023-07-02 Doctor小雷来自重庆

偏重的研究方向：肝癌
经验分享：刚刚一个月还是 10 reviewers invited

45 30

展开30条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157446, encodeId=2d6d215e44647, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;综述 经验分享：2023-8-21 received 2023-8-22 first revision 2023-8-30 second revision 2023-9-1 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ae8495390, createdName=ms1000001342961891, createdTime=Wed Sep 13 00:24:55 CST 2023, time=2023-09-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161407, encodeId=9aed216140ee1, content=求endnote格式 qq873770829, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Sat Oct 07 20:38:10 CST 2023, time=2023-10-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2157417, encodeId=4ebd215e41773, content=偏重的研究方向：肿瘤;综述 经验分享：Submission received 2023-8-15 Submission is under technical check 2023-8-15 Submission passed technical check 2023-8-16 Submission under peer review 2023-8-15 1 Reviewer accepted 2023-9-1 2 Reviewer accepted 2023-9-4 1 Reviewer report received 2023-09-11 Awaiting , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue Sep 12 22:20:02 CST 2023, time=2023-09-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2157661, encodeId=e421215e66126, content=集中回答一下，此期刊24年1月1号后会变成完全OA期刊。从今年9月13号以后提交的文章如果接收发表将支付APC。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff46407323, createdName=ms5000000493892071, createdTime=Thu Sep 14 13:22:04 CST 2023, time=2023-09-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2154696, encodeId=82242154696a6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：生信+WB验证;肿瘤 经验分享：记录一下，今天距离我投稿刚满一个月，目前状态依然是正在邀请5个审稿人，求求了，审稿人们接受审稿吧~等着毕业咧，等不起哇~（接评论区大神们的accept，接心软审稿人~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884e8240952, createdName=ms7000001703629541, createdTime=Sat Aug 26 17:10:22 CST 2023, time=2023-08-26, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向：肝癌 经验分享：刚刚一个月还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160146, encodeId=dc1a2160146c3, content=请问大家track all subbmission这个选项还有吗？从昨天开始我的就不见了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c18483515, createdName=ms8000001640264275, createdTime=Thu Sep 28 08:36:28 CST 2023, time=2023-09-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2159882, encodeId=10d6215988257, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：垃圾期刊，谁投谁后悔，不复当年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Tue Sep 26 20:52:53 CST 2023, time=2023-09-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161005, encodeId=cf48216100509, content=偏重的研究方向：泌尿外科;肿瘤;影像学 经验分享：一个月了，还是没有审稿人接受审稿，会怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2586476968, createdName=ms4000001917969473, createdTime=Thu Oct 05 09:52:57 CST 2023, time=2023-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157694, encodeId=6e5c215e694ca, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：当天投，当天拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9278140959, createdName=ms3000001761424859, createdTime=Thu Sep 14 16:09:53 CST 2023, time=2023-09-14, status=1, ipAttribution=山西省)]

2023-09-28 ms8000001640264275 来自上海

请问大家track all subbmission这个选项还有吗？从昨天开始我的就不见了

20 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157446, encodeId=2d6d215e44647, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;综述 经验分享：2023-8-21 received 2023-8-22 first revision 2023-8-30 second revision 2023-9-1 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ae8495390, createdName=ms1000001342961891, createdTime=Wed Sep 13 00:24:55 CST 2023, time=2023-09-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161407, encodeId=9aed216140ee1, content=求endnote格式 qq873770829, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Sat Oct 07 20:38:10 CST 2023, time=2023-10-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2157417, encodeId=4ebd215e41773, content=偏重的研究方向：肿瘤;综述 经验分享：Submission received 2023-8-15 Submission is under technical check 2023-8-15 Submission passed technical check 2023-8-16 Submission under peer review 2023-8-15 1 Reviewer accepted 2023-9-1 2 Reviewer accepted 2023-9-4 1 Reviewer report received 2023-09-11 Awaiting , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue Sep 12 22:20:02 CST 2023, time=2023-09-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2157661, encodeId=e421215e66126, content=集中回答一下，此期刊24年1月1号后会变成完全OA期刊。从今年9月13号以后提交的文章如果接收发表将支付APC。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff46407323, createdName=ms5000000493892071, createdTime=Thu Sep 14 13:22:04 CST 2023, time=2023-09-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2154696, encodeId=82242154696a6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：生信+WB验证;肿瘤 经验分享：记录一下，今天距离我投稿刚满一个月，目前状态依然是正在邀请5个审稿人，求求了，审稿人们接受审稿吧~等着毕业咧，等不起哇~（接评论区大神们的accept，接心软审稿人~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884e8240952, createdName=ms7000001703629541, createdTime=Sat Aug 26 17:10:22 CST 2023, time=2023-08-26, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向：肝癌 经验分享：刚刚一个月还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160146, encodeId=dc1a2160146c3, content=请问大家track all subbmission这个选项还有吗？从昨天开始我的就不见了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c18483515, createdName=ms8000001640264275, createdTime=Thu Sep 28 08:36:28 CST 2023, time=2023-09-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2159882, encodeId=10d6215988257, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：垃圾期刊，谁投谁后悔，不复当年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Tue Sep 26 20:52:53 CST 2023, time=2023-09-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161005, encodeId=cf48216100509, content=偏重的研究方向：泌尿外科;肿瘤;影像学 经验分享：一个月了，还是没有审稿人接受审稿，会怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2586476968, createdName=ms4000001917969473, createdTime=Thu Oct 05 09:52:57 CST 2023, time=2023-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157694, encodeId=6e5c215e694ca, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：当天投，当天拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9278140959, createdName=ms3000001761424859, createdTime=Thu Sep 14 16:09:53 CST 2023, time=2023-09-14, status=1, ipAttribution=山西省)]

2023-09-26 ms4000000681775086 来自福建省

审稿速度:24.0 | 投稿命中率:5.0
经验分享：垃圾期刊，谁投谁后悔，不复当年

34 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157446, encodeId=2d6d215e44647, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;综述 经验分享：2023-8-21 received 2023-8-22 first revision 2023-8-30 second revision 2023-9-1 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ae8495390, createdName=ms1000001342961891, createdTime=Wed Sep 13 00:24:55 CST 2023, time=2023-09-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161407, encodeId=9aed216140ee1, content=求endnote格式 qq873770829, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Sat Oct 07 20:38:10 CST 2023, time=2023-10-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2157417, encodeId=4ebd215e41773, content=偏重的研究方向：肿瘤;综述 经验分享：Submission received 2023-8-15 Submission is under technical check 2023-8-15 Submission passed technical check 2023-8-16 Submission under peer review 2023-8-15 1 Reviewer accepted 2023-9-1 2 Reviewer accepted 2023-9-4 1 Reviewer report received 2023-09-11 Awaiting , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue Sep 12 22:20:02 CST 2023, time=2023-09-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2157661, encodeId=e421215e66126, content=集中回答一下，此期刊24年1月1号后会变成完全OA期刊。从今年9月13号以后提交的文章如果接收发表将支付APC。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff46407323, createdName=ms5000000493892071, createdTime=Thu Sep 14 13:22:04 CST 2023, time=2023-09-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2154696, encodeId=82242154696a6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：生信+WB验证;肿瘤 经验分享：记录一下，今天距离我投稿刚满一个月，目前状态依然是正在邀请5个审稿人，求求了，审稿人们接受审稿吧~等着毕业咧，等不起哇~（接评论区大神们的accept，接心软审稿人~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884e8240952, createdName=ms7000001703629541, createdTime=Sat Aug 26 17:10:22 CST 2023, time=2023-08-26, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向：肝癌 经验分享：刚刚一个月还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160146, encodeId=dc1a2160146c3, content=请问大家track all subbmission这个选项还有吗？从昨天开始我的就不见了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c18483515, createdName=ms8000001640264275, createdTime=Thu Sep 28 08:36:28 CST 2023, time=2023-09-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2159882, encodeId=10d6215988257, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：垃圾期刊，谁投谁后悔，不复当年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Tue Sep 26 20:52:53 CST 2023, time=2023-09-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161005, encodeId=cf48216100509, content=偏重的研究方向：泌尿外科;肿瘤;影像学 经验分享：一个月了，还是没有审稿人接受审稿，会怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2586476968, createdName=ms4000001917969473, createdTime=Thu Oct 05 09:52:57 CST 2023, time=2023-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157694, encodeId=6e5c215e694ca, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：当天投，当天拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9278140959, createdName=ms3000001761424859, createdTime=Thu Sep 14 16:09:53 CST 2023, time=2023-09-14, status=1, ipAttribution=山西省)]

2023-10-05 ms4000001917969473

偏重的研究方向：泌尿外科;肿瘤;影像学
经验分享：一个月了，还是没有审稿人接受审稿，会怎么办？

20 0

[GetPortalCommentsPageByObjectIdResponse(id=2157446, encodeId=2d6d215e44647, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;综述 经验分享：2023-8-21 received 2023-8-22 first revision 2023-8-30 second revision 2023-9-1 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ae8495390, createdName=ms1000001342961891, createdTime=Wed Sep 13 00:24:55 CST 2023, time=2023-09-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161407, encodeId=9aed216140ee1, content=求endnote格式 qq873770829, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cf5464123, createdName=可乐雪碧, createdTime=Sat Oct 07 20:38:10 CST 2023, time=2023-10-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2157417, encodeId=4ebd215e41773, content=偏重的研究方向：肿瘤;综述 经验分享：Submission received 2023-8-15 Submission is under technical check 2023-8-15 Submission passed technical check 2023-8-16 Submission under peer review 2023-8-15 1 Reviewer accepted 2023-9-1 2 Reviewer accepted 2023-9-4 1 Reviewer report received 2023-09-11 Awaiting , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue Sep 12 22:20:02 CST 2023, time=2023-09-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2157661, encodeId=e421215e66126, content=集中回答一下，此期刊24年1月1号后会变成完全OA期刊。从今年9月13号以后提交的文章如果接收发表将支付APC。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff46407323, createdName=ms5000000493892071, createdTime=Thu Sep 14 13:22:04 CST 2023, time=2023-09-14, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2154696, encodeId=82242154696a6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：生信+WB验证;肿瘤 经验分享：记录一下，今天距离我投稿刚满一个月，目前状态依然是正在邀请5个审稿人，求求了，审稿人们接受审稿吧~等着毕业咧，等不起哇~（接评论区大神们的accept，接心软审稿人~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884e8240952, createdName=ms7000001703629541, createdTime=Sat Aug 26 17:10:22 CST 2023, time=2023-08-26, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向：肝癌 经验分享：刚刚一个月还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160146, encodeId=dc1a2160146c3, content=请问大家track all subbmission这个选项还有吗？从昨天开始我的就不见了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c18483515, createdName=ms8000001640264275, createdTime=Thu Sep 28 08:36:28 CST 2023, time=2023-09-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2159882, encodeId=10d6215988257, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：垃圾期刊，谁投谁后悔，不复当年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Tue Sep 26 20:52:53 CST 2023, time=2023-09-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161005, encodeId=cf48216100509, content=偏重的研究方向：泌尿外科;肿瘤;影像学 经验分享：一个月了，还是没有审稿人接受审稿，会怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2586476968, createdName=ms4000001917969473, createdTime=Thu Oct 05 09:52:57 CST 2023, time=2023-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157694, encodeId=6e5c215e694ca, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：当天投，当天拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9278140959, createdName=ms3000001761424859, createdTime=Thu Sep 14 16:09:53 CST 2023, time=2023-09-14, status=1, ipAttribution=山西省)]

2023-09-14 ms3000001761424859 来自山西省

投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：当天投，当天拒

22 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务